Sarepta Cut to Neutral at Citi on Risks to Valuation

Seeking AlphaJun 26 21:10

Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty

Catalent shares rise after Sarepta Therapeutics' Elevidys expanded approval. Despite uncertainties, Catalent's risk/reward profile improves.

Analyst UpgradesJun 22 01:52

Catalent Gains After Sarepta's Elevidys Gets Label Expansion

Seeking AlphaJun 21 22:03

Pharmaceutical Contract Manufacturing Market Report 2024-2030: Trends, Opportunities and Competitive Analysis Featuring Thermo Fisher Scientific, Catalent, Lonza, Almac Group, and Recipharm

Yahoo FinanceJun 21 21:44

Express News | Shares of Contract Drug Manufacturer Catalent up 3.3% After FDA's Expanded Use Nod for Sarepta's Duchenne Gene Therapy

BreakingsJun 21 21:32

Japan Contract Development Manufacturing Organization Market Report 2024-2030, Featuring Lonza, Recipharm, LabCorp, Catalent, WuXi AppTec, CordenPharma, Cambrex, Bushu Pharmaceuticals and Nipro

Yahoo FinanceJun 21 16:50